You are here

HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal.

TitleHIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal.
Publication TypeJournal Article
Year of Publication2008
AuthorsGottlieb, GS, Hawes, SE, Wong, KG, Raugi, DN, Agne, HD, Critchlow, CW, Kiviat, NB, Sow, PSalif
JournalAIDS Res Hum Retroviruses
Volume24
Issue6
Pagination857-64
Date Published2008 Jun
ISSN1931-8405
KeywordsAdult, Amino Acid Sequence, Anti-HIV Agents, Cervix Uteri, Drug Resistance, Viral, env Gene Products, Human Immunodeficiency Virus, Female, HIV Infections, HIV Protease, HIV Reverse Transcriptase, HIV-2, Humans, Leukocytes, Mononuclear, Likelihood Functions, Middle Aged, Molecular Sequence Data, Mutation, Phylogeny, Polymorphism, Genetic, RNA, Viral, Senegal, Sequence Analysis, Protein, Vagina
Abstract

Unique viral variants and resistance mutations may occur in the genital tract of HIV-2 ARV-naive infected women. We sequenced and phylogenetically analyzed protease (PR), reverse transcriptase (RT), and envelope (ENV) from PBMC and genital tract samples from four ARV-naive women in Senegal. HIV-2 protease polymorphisms that predict HIV-1 protease inhibitor (PI) resistance were common. Two subjects had protease mutations (T77I and I64V) in genital tract samples that were not found in PBMCs. One subject had the HIV-2 reverse transcriptase M184I mutation in CVL DNA (but not PBMCs) that is known to confer 3TC/FTC resistance in HIV-2. In another subject, the reverse transcriptase A62V mutation was also found in CVL-RNA but not PBMCs. We found no significant difference in ENV variants between PBMCs and the genital tract. HIV-2 RT and PR mutations in the genital tract of ARV-naive females may have implications for transmitted HIV-2 resistance and ARV therapy.

DOI10.1089/aid.2008.0015
Alternate JournalAIDS Res. Hum. Retroviruses
PubMed ID18544024